Royalty Pharma
RPRX
RPRX
451 hedge funds and large institutions have $12.3B invested in Royalty Pharma in 2025 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 170 increasing their positions, 154 reducing their positions, and 63 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
8.01% more ownership
Funds ownership: 73.08% → 81.09% (+8%)
2% more funds holding
Funds holding: 442 → 451 (+9)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Holders
451
Holding in Top 10
6
Calls
$81.6M
Puts
$17.9M
Top Buyers
| 1 | +$788M | |
| 2 | +$201M | |
| 3 | +$166M | |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$58.2M |
| 5 |
Amundi
Paris,
France
|
+$56.5M |
Top Sellers
| 1 | -$287M | |
| 2 | -$74.1M | |
| 3 | -$74M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$71.5M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$60M |
